In clinical management, controlling intestinal inflammatory activity by employing targeted therapies such as anti-TNF-α and JAK inhibitors, combined with psychological interventions and MDT approaches, is of significant importance for preventing and improving IBD-related ED. The gene discussed is TNF; the disease is irritable bowel syndrome.